Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting

Rhea-AI Summary

Tiziana Life Sciences held its Annual General Meeting on June 25, 2021, where all resolutions were approved. The company announced the re-activation of its strategic plan to redomicile to Bermuda, with further information to be provided to shareholders. The results of proxy voting will be available on the company's website.

Tiziana Life Sciences focuses on developing novel therapies in oncology and immunology, including Milciclib and Foralumab, a second generation human anti-CD3 monoclonal antibody for various autoimmune diseases.

Positive

• Resolutions at the Annual General Meeting were unanimously passed.
• Re-activation of strategic plan to redomicile to Bermuda may benefit operational execution.

Negative

• None.

LONDON, June 25, 2021 (GLOBE NEWSWIRE) -- At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed.

The results of the proxy voting will be available shortly on the Company's website, https://ir.tizianalifesciences.com/shareholder-services/annual-general-meeting.

The Company also confirms that it has re-activated its strategic plan to redomicile to Bermuda; shareholders will receive further information in due course.

The person who arranged for the release of this announcement was Keeren Shah, Chief Financial Officer.

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory pulmonary diseases.     

For further enquiries: United Kingdom:
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder	+44 (0)20 7495 2379
United States: Investors: Dave Gentry, CEO RedChip Companies Inc. 1-800-RED-CHIP (733-2447) or 407-491-4498 dave@redchip.com

FAQ

What happened at Tiziana Life Sciences' Annual General Meeting on June 25, 2021?

All resolutions were passed during the Annual General Meeting.

What is the significance of Tiziana Life Sciences' decision to redomicile to Bermuda?

The redomiciling could enhance operational efficiency and regulatory advantages.

Where can I find the proxy voting results for Tiziana Life Sciences?

The proxy voting results will be available on the company's website soon.

What are the main products being developed by Tiziana Life Sciences?

Key products include Milciclib and Foralumab, targeting oncology and autoimmune diseases.

Which diseases is Foralumab being developed to treat?

Foralumab is being developed for COVID-19, multiple sclerosis, Crohn's disease, and other autoimmune conditions.